Related Experiment Video
Updated: Jun 20, 2025
Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells
Published on: May 20, 2015
Structure-Guided Identification of Novel Aromatase Inhibitors Targeting Breast Carcinoma
Priyanka Yadav1, Manish Kumar Tripathi2, Manoj Kumar Yadav3
1Department of Biotechnology, SRM University, Delhi-NCR, Sonepat, 131029, India.
Abstract:
Aromatase inhibitors play a critical therapeutic role in treating ER+ breast cancer, especially in postmenopausal women. However, their efficacy is often limited by resistance and severe side effects. Identifying new compounds that can disrupt aromatase enzyme function is essential. In this study, structural anomalies in the aromatase enzyme were corrected through energy minimization, and the structure was validated via Ramachandran plot. We screened 170,269 natural compounds from the ASINEX Biodesign library using high-throughput screening algorithms to target the aromatase enzyme. Molecular docking identified three compounds: BDD30170158, BDE33872639, and BDE30177677, all showing stable binding interactions with the aromatase enzyme. Molecular dynamics simulations over 100 ns confirmed the conformational stability of these compounds. Although all three compounds exhibited the desired pharmacokinetic and drug metabolism properties, only one compound (BDE33872639) was identified as a non-blocker, demonstrating a reduced risk of adverse cardiac effects. This compound exhibits significant potential as a novel aromatase inhibitor, warranting further experimental research to develop it as a therapeutic option for ER+ breast cancer.
Insights
Researchers identified a novel compound, BDE33872639, as a potential non-cardiotoxic aromatase inhibitor. This discovery offers a promising new therapeutic avenue for estrogen receptor-positive breast cancer treatment.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Oncology
Background:
- Aromatase inhibitors are crucial for treating estrogen receptor-positive (ER+) breast cancer in postmenopausal women.
- Resistance and side effects limit current aromatase inhibitor efficacy.
- Novel compounds targeting aromatase are needed to overcome these limitations.
Purpose of the Study:
- To identify novel natural compounds with aromatase inhibitory activity.
- To evaluate the safety and efficacy of potential drug candidates through computational methods.
Main Methods:
- Energy minimization and Ramachandran plot analysis to refine aromatase enzyme structure.
- High-throughput virtual screening of 170,269 natural compounds against aromatase.
- Molecular docking and 100 ns molecular dynamics simulations to assess binding stability and interactions.
- Pharmacokinetic and drug metabolism property evaluation.
Main Results:
- Three compounds (BDD30170158, BDE33872639, BDE30177677) showed stable binding to the aromatase enzyme.
- All identified compounds possessed favorable pharmacokinetic and drug metabolism profiles.
- Compound BDE33872639 was identified as a non-blocker with a lower risk of cardiac side effects.
Conclusions:
- Compound BDE33872639 demonstrates significant potential as a novel, safer aromatase inhibitor.
- Further experimental validation is warranted to develop BDE33872639 for ER+ breast cancer therapy.
